Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 1...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Pinnix, Chelsea C., Gunther, Jillian R., Dabaja, Bouthaina S., Strati, Paolo, Fang, Penny, Hawkins, Misha C., Adkins, Sherry, Westin, Jason, Ahmed, Sairah, Fayad, Luis, Lee, Hun Ju, Nair, Ranjit, Steiner, Raphael E., Iyer, Swaminathan P., Rodriguez, M. Alma, Wang, Michael, Flowers, Christopher, Neelapu, Sattva S., Nastoupil, Loretta J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362355/
https://ncbi.nlm.nih.gov/pubmed/32589728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001837
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller